Extended-release melatonin isn’t universally better, but it solves a different problem than the standard form. If you fall asleep fine but keep waking up during the night, extended-release is the stronger choice. If your main issue is falling asleep in the first place, immediate-release works just as well or better. The right formulation depends on what’s actually disrupting your sleep.
How the Two Formulations Work Differently
Your body naturally produces melatonin in a slow, sustained wave that starts in the evening and lasts through the night. Immediate-release melatonin doesn’t mimic that pattern. It hits your bloodstream fast, peaking in about 50 minutes, then clears out with a half-life of roughly one hour. That means levels drop off well before dawn.
Extended-release (also called sustained-release or prolonged-release) melatonin takes a bit longer to peak, around 1.25 hours, but stays in your system dramatically longer. In a pharmacokinetic comparison, the half-life of extended-release melatonin was about 5 hours, five times longer than the immediate-release version. That sustained presence keeps blood levels elevated across an 8-hour sleep window, then tapers off gradually so you’re not groggy in the morning.
Falling Asleep vs. Staying Asleep
This is the practical distinction that matters most. Immediate-release melatonin delivers a higher initial spike in blood concentration. That sharp peak is what signals your brain that it’s time to sleep, making it effective for reducing the time it takes to fall asleep. Extended-release formulations, because they release melatonin gradually, produce a lower peak concentration. In one study, the controlled-release version produced roughly half the peak blood levels compared to immediate-release at the same dose.
For staying asleep, the picture flips. Extended-release melatonin maintains consistent levels throughout the night, which helps reduce middle-of-the-night awakenings. In clinical cases where patients were waking two to four times per night, switching to a timed-release formulation reduced awakenings to zero or once per night. Some clinicians even combine a small immediate-release dose (for falling asleep) with an extended-release dose (for staying asleep) when patients have trouble with both.
If you mostly struggle with sleep onset, particularly from jet lag or an inconsistent schedule, immediate-release is the more targeted option. Meta-analyses consistently show melatonin modestly reduces the time it takes to fall asleep, and that effect is driven largely by the initial surge that immediate-release delivers best.
The Strongest Evidence Is for Adults Over 55
Extended-release melatonin has the most robust clinical backing for older adults, and there’s a biological reason for that. Melatonin production naturally declines with age, and the prevalence of insomnia rises in parallel. Older adults aren’t just making less melatonin; they’re losing the sustained overnight release pattern that keeps sleep consolidated.
A prolonged-release formulation called Circadin (2 mg) is the only melatonin product approved as a prescription medicine in Europe, specifically for adults aged 55 and older with primary insomnia. In a trial of 354 patients aged 55 to 80, those taking the prolonged-release formulation fell asleep about 24 minutes faster compared to roughly 13 minutes with placebo. More notably, sleep quality, morning alertness, and overall quality of life all improved significantly. The response rate, meaning patients who experienced meaningful improvement in both sleep quality and morning alertness, was 26% on melatonin versus 15% on placebo.
That sleep latency reduction of about 24 minutes is comparable to what conventional sleep medications achieve in this age group, but without the dependency risk or cognitive side effects that make those drugs problematic for older adults.
For Children With Sleep Disorders
Prolonged-release melatonin has also been studied in children and adolescents with autism spectrum disorder and insomnia, where sleep-maintenance difficulties are common. In a two-year study of 80 children aged 2 to 17, nightly doses of 2, 5, or 10 mg of a pediatric prolonged-release formulation were found to be safe and effective for long-term use. This is notable because most melatonin research involves short treatment periods, and parents of children with neurodevelopmental conditions often need a longer-term solution.
Shift Work and Jet Lag
For jet lag, melatonin has good evidence for improving alertness and reducing daytime sleepiness during adjustment. But the benefit here is primarily about timing your body’s clock, not sustaining sleep through the night. Immediate-release melatonin, taken at the right time, is generally the preferred choice because the goal is to send a sharp “it’s nighttime” signal to your brain.
For shift work disorder, the evidence is less encouraging regardless of formulation. It’s not clear that melatonin meaningfully improves daytime sleep quality or duration for people working overnight shifts. The challenge with shift work is that you’re fighting powerful light exposure cues, and melatonin alone often can’t override those signals.
Choosing the Right Dose
Clinical trials of extended-release melatonin have used doses ranging from 2 mg to 10 mg, depending on the population. The European prescription product uses just 2 mg. Many over-the-counter extended-release products in the U.S. come in 3 mg or 5 mg doses. Higher isn’t necessarily better with melatonin. Because it’s a hormone rather than a sedative, excessive doses can lead to desensitization of melatonin receptors or disrupt your circadian rhythm rather than support it.
If you’re trying extended-release melatonin, starting at 2 to 3 mg is reasonable for most adults. The 5 mg dose is common in clinical practice, particularly for people who haven’t responded to lower amounts. Doses of 10 mg are typically reserved for specific clinical situations, such as children with autism-related insomnia under medical supervision.
Practical Considerations
Timing matters more with immediate-release melatonin than with extended-release. Because immediate-release peaks quickly and clears fast, taking it too early means it may wear off before you’re deeply asleep. Most people take it 20 to 30 minutes before bed. Extended-release is more forgiving on timing since it delivers melatonin over several hours, but taking it at a consistent time each night reinforces your circadian rhythm.
One concern people have with extended-release formulations is morning grogginess. The pharmacokinetic data is actually reassuring here: a well-designed extended-release product tapers melatonin levels gradually so they’re low by the time you wake. In the Circadin trial, morning alertness actually improved compared to placebo, suggesting the formulation didn’t cause a “hangover” effect. That said, poorly formulated supplements could release too much melatonin too late in the night. Since over-the-counter melatonin isn’t regulated as strictly as prescription drugs in the U.S., quality varies between brands.
If you’re waking up groggy after trying extended-release melatonin, the dose may be too high, or the product’s release profile may not match what’s on the label. Trying a lower dose or a different brand is a practical first step.